Standard Total Knee Arthroplasty Using Platelet Rich Plasma (PRP)
Primary Purpose
Osteoarthritis
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Total knee arthroplasty
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis focused on measuring PRP, TKA, pain scale, hemoglobin, hematocrit, narcotics
Eligibility Criteria
Inclusion Criteria:
- Patient is a male or female who is undergoing primary unilateral surgery or the first surgery of a staged bilateral total knee replacement where the second stage will be at least 6 weeks later
- Patient agrees to be blinded to their treatment group assignment
- Patient is willing and able to return for follow-up over at least a six (6) month post-operative period although longer follow-up may be desired
- Patient agrees to participate by signing an IRB approved Informed Consent Form
Exclusion Criteria:
- Patient will have a staged bilateral total knee replacement with the second stage to be performed less than 6 weeks after the first stage surgery PRP in
- Patient has had previous surgery on the operative knee that will necessitate the removal of existing hardware (e.g. previous osteotomy)
- Patient has a known adverse reaction or sensitivity to bovine (cow) thrombin (used as part of the platelet rich plasma system) or other bovine-derived products
- Patient has hemoglobin < 12.0 (males), < 11.0 (females)
- Patient has a clinically significant anxiety disorder
- Patient is on therapeutic anticoagulation medication and has an INR > 1.3
- Patient has a severe bleeding disorder
- Patient has a known addiction to drugs or alcohol, including, but not limited to: chronic daily use of narcotic medications for more than 90 days prior to surgery
- Patient is pregnant
- Patient is a prisoner
- Patient is involved in a personal litigation (e.g. Worker's Compensation) that relates to their knee surgery
- Patient is actively participating in another medical device, drug, or biologic clinical trial (active defined as having treatment within the last 30 days)
Sites / Locations
- Henrico Doctors' Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Standard TKA
Standard TKA with PRP
Arm Description
Subjects in this arm will receive total knee replacement as standard of care without Platte Rich Plasma
Subjects in this arm will receive total knee replacement as standard of care with Platte Rich Plasma
Outcomes
Primary Outcome Measures
Change in hemoglobin (Hgb) level
Hemoglobin level analysis
Secondary Outcome Measures
Visual analog scale (VAS) for pain
Visual analog scale for Pain (1-10), 10 being the worst
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01075230
Brief Title
Standard Total Knee Arthroplasty Using Platelet Rich Plasma (PRP)
Official Title
A Prospective, Randomized, Single-blind, Multi-center Clinical Study to Evaluate the Effect of Platelet Rich Plasma (PRP) on Short-term Patient Outcomes Following Total Knee Replacement.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Terminated
Why Stopped
Intended as multi-center. 1 of 2 sites could not participate. Enrollment discontinued after 50/100. Subjects followed per protocol.
Study Start Date
February 2010 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Exactech
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Clinical study to determine if there is a difference in hemoglobin level between patients undergoing total knee arthroplasty with and without platelet-rich plasma.
Detailed Description
The purpose of this study is to determine if there is a difference in hemoglobin level between patients undergoing total knee arthroplasty with and without platelet-rich plasma.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
PRP, TKA, pain scale, hemoglobin, hematocrit, narcotics
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Standard TKA
Arm Type
Active Comparator
Arm Description
Subjects in this arm will receive total knee replacement as standard of care without Platte Rich Plasma
Arm Title
Standard TKA with PRP
Arm Type
Active Comparator
Arm Description
Subjects in this arm will receive total knee replacement as standard of care with Platte Rich Plasma
Intervention Type
Procedure
Intervention Name(s)
Total knee arthroplasty
Other Intervention Name(s)
Optetrak total knee system
Intervention Description
Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
Primary Outcome Measure Information:
Title
Change in hemoglobin (Hgb) level
Description
Hemoglobin level analysis
Time Frame
Preop, post-op day 2
Secondary Outcome Measure Information:
Title
Visual analog scale (VAS) for pain
Description
Visual analog scale for Pain (1-10), 10 being the worst
Time Frame
Preop, post-op day 1, post-op day 2, discharge, 6 weeks
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is a male or female who is undergoing primary unilateral surgery or the first surgery of a staged bilateral total knee replacement where the second stage will be at least 6 weeks later
Patient agrees to be blinded to their treatment group assignment
Patient is willing and able to return for follow-up over at least a six (6) month post-operative period although longer follow-up may be desired
Patient agrees to participate by signing an IRB approved Informed Consent Form
Exclusion Criteria:
Patient will have a staged bilateral total knee replacement with the second stage to be performed less than 6 weeks after the first stage surgery PRP in
Patient has had previous surgery on the operative knee that will necessitate the removal of existing hardware (e.g. previous osteotomy)
Patient has a known adverse reaction or sensitivity to bovine (cow) thrombin (used as part of the platelet rich plasma system) or other bovine-derived products
Patient has hemoglobin < 12.0 (males), < 11.0 (females)
Patient has a clinically significant anxiety disorder
Patient is on therapeutic anticoagulation medication and has an INR > 1.3
Patient has a severe bleeding disorder
Patient has a known addiction to drugs or alcohol, including, but not limited to: chronic daily use of narcotic medications for more than 90 days prior to surgery
Patient is pregnant
Patient is a prisoner
Patient is involved in a personal litigation (e.g. Worker's Compensation) that relates to their knee surgery
Patient is actively participating in another medical device, drug, or biologic clinical trial (active defined as having treatment within the last 30 days)
Facility Information:
Facility Name
Henrico Doctors' Hospital
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23294
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Standard Total Knee Arthroplasty Using Platelet Rich Plasma (PRP)
We'll reach out to this number within 24 hrs